National Research Corporation (NASDAQ:NRC - Free Report) - Analysts at Citizens Jmp issued their Q3 2026 earnings per share estimates for National Research in a research report issued to clients and investors on Tuesday, September 29th. Citizens Jmp analyst C. Davides forecasts that the company will post earnings of $0.21 per share for the quarter. Citizens Jmp currently has a "Market Outperform" rating and a $26.00 target price on the stock. Citizens Jmp also issued estimates for National Research's Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.98 EPS and FY2027 earnings at $1.05 EPS.
A number of other equities analysts also recently commented on the stock. Weiss Ratings raised shares of National Research from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, August 21st. Wall Street Zen cut shares of National Research from a "buy" rating to a "hold" rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $26.00.
Check Out Our Latest Report on National Research
National Research Trading Up 2.1%
Shares of National Research stock opened at $20.78 on Tuesday. The firm has a market capitalization of $472.66 million, a PE ratio of 83.12 and a beta of 0.25. The company has a debt-to-equity ratio of 13.13, a current ratio of 0.65 and a quick ratio of 0.65. The company's fifty day moving average price is $21.00 and its two-hundred day moving average price is $19.77. National Research has a 52-week low of $11.01 and a 52-week high of $23.68.
National Research (NASDAQ:NRC - Get Free Report) last issued its earnings results on Tuesday, July 28th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.46. National Research had a return on equity of 164.26% and a net margin of 4.18%.The business had revenue of $35.39 million during the quarter, compared to analyst estimates of $34.90 million.
National Research Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, October 9th. Stockholders of record on Friday, September 25th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. National Research's payout ratio is 256.00%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC bought a new stake in shares of National Research in the first quarter worth $180,000. Empowered Funds LLC bought a new stake in National Research during the 1st quarter worth about $226,000. DGS Capital Management LLC acquired a new position in shares of National Research during the 4th quarter worth about $274,000. Morgan Dempsey Capital Management LLC bought a new position in shares of National Research in the 4th quarter valued at about $296,000. Finally, Empirical Finance LLC acquired a new stake in shares of National Research in the second quarter valued at about $431,000. 47.26% of the stock is owned by institutional investors and hedge funds.
About National Research
(
Get Free Report)
National Research Corporation, formerly traded on the Nasdaq under the symbol NRC and known as NRC Health, provides market research, analytics and performance-improvement services to healthcare organizations. Its solutions are designed to help hospitals, health systems and other providers understand the experiences and expectations of patients, employees, physicians and communities.
The company's offerings have included patient-experience measurement, employee and physician engagement surveys, reputation and brand research, community health assessments, data analytics and advisory services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider National Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Research wasn't on the list.
While National Research currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
